U.S FDA issues 5 observations to Aurobindo Pharma arm’s facility in AP  


The U.S. Food and Drug Administration (U.S. FDA) has issued five observations to Aurobindo Pharma stepdown subsidiary Eugia Steriles’ facility in Andhra Pradesh.

The observations were issued after a pre-approval inspection (PAI) of the facility in Parawada mandal, Anakapalli district, from February 10-18. The observations are procedural in nature and will be responded to within the stipulated time, Aurobindo Pharma said in a filing on Tuesday.

Eugia Steriles is a 100% subsidiary of Eugia Pharma Specialities and a stepdown subsidiary of the company.



Source link

  • Related Posts

    Lupin, China’s SUP ink pact for COPD drug Tiotropium DPI

    Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for commercialisation of chronic obstructive pulmonary disease drug Tiotropium Dry Powder Inhaler, 18 mcg/capsule, in the Chinese…

    Continue reading
    India to export 150 locomotives to Africa worth over ₹3,000 crore

    “These locomotives are fitted with Distributed Power Wireless Control System, or DPWCS, for synchronised operations and superior freight handling,” a Railways Ministry spokesperson said. Photo: https://www.wabteccorp.com/ India will supply 150…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *